DRI Healthcare Trust (TSE:DHT.UN) Stock Jumps 0.1% – Here’s Why

DRI Healthcare Trust (TSE:DHT.UN) traded up 0.1% during mid-day trading on Thursday. The stock traded as high as C$19.17 and last traded at C$18.77. Approximately 48,368 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 53,404 shares. The stock had previously closed at C$18.75.

Analyst Ratings Changes

DHT.UN has been the subject of a number of recent research reports. National Bank Financial upped their price objective on DRI Healthcare Trust from C$23.50 to C$25.50 and gave the stock an “outperform” rating in a research note on Tuesday, September 22nd. Stifel Nicolaus increased their target price on DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of C$25.60.

DRI Healthcare Trust Trading Up 0.1%

The company’s 50-day moving average is C$17.96 and its two-hundred day moving average is C$17.32. The stock has a market capitalization of C$1.03 billion, a P/E ratio of -23.46 and a beta of 0.09.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.